PL2536399T3 - Sposób aktywacji i sprzęgania biocząsteczek - Google Patents

Sposób aktywacji i sprzęgania biocząsteczek

Info

Publication number
PL2536399T3
PL2536399T3 PL11745404T PL11745404T PL2536399T3 PL 2536399 T3 PL2536399 T3 PL 2536399T3 PL 11745404 T PL11745404 T PL 11745404T PL 11745404 T PL11745404 T PL 11745404T PL 2536399 T3 PL2536399 T3 PL 2536399T3
Authority
PL
Poland
Prior art keywords
biomolecules
conjugation
activation
Prior art date
Application number
PL11745404T
Other languages
English (en)
Inventor
Jens H. Vogel
Chi Shung Brian To
Carolina Lucia Bianco
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PL2536399T3 publication Critical patent/PL2536399T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025—Reverse osmosis; Hyperfiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
PL11745404T 2010-02-21 2011-02-21 Sposób aktywacji i sprzęgania biocząsteczek PL2536399T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30651310P 2010-02-21 2010-02-21
PCT/US2011/025592 WO2011103531A1 (en) 2010-02-21 2011-02-21 Method for Activation and Conjugation of Biomolecules
EP11745404.1A EP2536399B1 (en) 2010-02-21 2011-02-21 Method for activation and conjugation of biomolecules

Publications (1)

Publication Number Publication Date
PL2536399T3 true PL2536399T3 (pl) 2020-06-29

Family

ID=44483343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11745404T PL2536399T3 (pl) 2010-02-21 2011-02-21 Sposób aktywacji i sprzęgania biocząsteczek

Country Status (34)

Country Link
US (1) US9254336B2 (pl)
EP (1) EP2536399B1 (pl)
JP (1) JP5726915B2 (pl)
KR (1) KR101776976B1 (pl)
CN (2) CN105664175B (pl)
AU (1) AU2011217794B2 (pl)
BR (1) BR112012020855B8 (pl)
CA (1) CA2790401C (pl)
CL (1) CL2012002306A1 (pl)
CO (1) CO6592111A2 (pl)
CR (1) CR20120437A (pl)
CU (1) CU20120121A7 (pl)
CY (1) CY1122711T1 (pl)
DK (1) DK2536399T3 (pl)
EA (1) EA201290804A1 (pl)
EC (1) ECSP12012112A (pl)
ES (1) ES2769629T3 (pl)
GT (1) GT201200244A (pl)
HR (1) HRP20192164T1 (pl)
HU (1) HUE047661T2 (pl)
IL (1) IL221447A (pl)
LT (1) LT2536399T (pl)
MX (1) MX2012009674A (pl)
NZ (1) NZ601905A (pl)
PE (1) PE20130003A1 (pl)
PH (2) PH12012501664A1 (pl)
PL (1) PL2536399T3 (pl)
PT (1) PT2536399T (pl)
RS (1) RS59827B1 (pl)
SG (1) SG183309A1 (pl)
SI (1) SI2536399T1 (pl)
UA (1) UA115221C2 (pl)
WO (1) WO2011103531A1 (pl)
ZA (2) ZA201206215B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE481323A (pl) * 1947-04-10
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-dpep3 항체 및 이의 사용 방법
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335383D1 (de) * 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US20070173634A1 (en) 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
BR112012001814A8 (pt) * 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
SG181628A1 (en) * 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions

Also Published As

Publication number Publication date
MX2012009674A (es) 2012-09-07
CN105664175A (zh) 2016-06-15
CA2790401A1 (en) 2011-08-25
CY1122711T1 (el) 2021-03-12
WO2011103531A1 (en) 2011-08-25
EA201290804A1 (ru) 2013-03-29
ECSP12012112A (es) 2012-10-30
PH12012501664A1 (en) 2012-10-22
CA2790401C (en) 2018-05-29
HRP20192164T1 (hr) 2020-03-06
EP2536399A4 (en) 2016-02-24
CN102970988A (zh) 2013-03-13
LT2536399T (lt) 2020-03-10
SI2536399T1 (sl) 2020-02-28
ZA201206215B (en) 2014-10-29
JP2013520441A (ja) 2013-06-06
EP2536399B1 (en) 2019-11-20
ES2769629T3 (es) 2020-06-26
SG183309A1 (en) 2012-09-27
KR20120120966A (ko) 2012-11-02
GT201200244A (es) 2014-09-02
CO6592111A2 (es) 2013-01-02
CN105664175B (zh) 2019-07-23
AU2011217794B2 (en) 2015-01-29
PH12016501602A1 (en) 2017-06-05
CL2012002306A1 (es) 2013-01-18
PT2536399T (pt) 2020-02-06
NZ601905A (en) 2014-09-26
CR20120437A (es) 2012-12-07
IL221447A (en) 2015-09-24
KR101776976B1 (ko) 2017-09-08
ZA201405941B (en) 2018-05-31
JP5726915B2 (ja) 2015-06-03
CN102970988B (zh) 2016-03-16
BR112012020855A2 (pt) 2017-08-29
HK1182330A1 (zh) 2013-11-29
PE20130003A1 (es) 2013-01-19
US20130040362A1 (en) 2013-02-14
US9254336B2 (en) 2016-02-09
EP2536399A1 (en) 2012-12-26
RS59827B1 (sr) 2020-02-28
AU2011217794A1 (en) 2012-09-20
BR112012020855B8 (pt) 2021-05-25
HK1225652A1 (zh) 2017-09-15
UA115221C2 (uk) 2017-10-10
CU20120121A7 (es) 2013-01-30
HUE047661T2 (hu) 2020-05-28
IL221447A0 (en) 2012-10-31
BR112012020855B1 (pt) 2021-05-04
DK2536399T3 (da) 2020-02-10

Similar Documents

Publication Publication Date Title
IL273399B (en) Methods and devices for the synthesis of nucleic acids
IL269804A (en) Conjugates of an active protein material and a method for their preparation
HRP20180882T1 (hr) Sredstva za i postupci liječenja dlbcl
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
GB201003922D0 (en) Conjugation process
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
GB201219222D0 (en) Method and system
ZA201302537B (en) Stable and soluble antibodies
ZA201204641B (en) Method for preparing and detoxifying
ZA201405941B (en) Method for activation and conjugation of biomolecules
GB2497035B (en) Method of authentication
EP2658898A4 (en) COUPLED POLYMERS AND METHODS FOR PREPARING THEM
GB2483684B (en) Range determination apparatus and method
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof
LT2630159T (lt) Stabilūs ir tirpūs antikūnai
PL392998A1 (pl) Sposób pozyskiwania mikropopiołów i układ do pozyskiwania mikropopiołów
GB201003916D0 (en) Conjugation process
GB201000806D0 (en) Apparatus and methods
GB201010290D0 (en) Apparatus and methods
GB201001384D0 (en) Light-fitting and associated methods